Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Semaglutide also delays gastric emptying ... but the label indicates thyroid cancer risk. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Animal studies have shown that using liraglutide (the active ingredient in Saxenda) or semaglutide (the active ingredient in Ozempic) may increase the risk of thyroid cancer. However, the risk of ...

However, semaglutide was not linked to a significantly reduced risk of developing thyroid, stomach, or breast cancer. Yoni Resnick, PharmD, the director of pharmacy clinical services with New ...

A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date.